MedTrace Logo

A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer

NCT03081819 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-09-11

No results posted yet for this study

Summary

A Phase I study of SH003 for evaluate safe dose range in patients with solid cancer.

The first dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated.

The second dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated.

The third dose group receives SH003 for 3 weeks.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

SH003

Herbal medicine for cancer treatment

Sponsors & Collaborators

  • Kyunghee University Medical Center

    lead OTHER

Study Design

Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-29
Primary Completion
2019-04-16
Completion
2019-07-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03081819 on ClinicalTrials.gov